Search Results - "Borbath, I"

Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Valle, J W, Borbath, I, Khan, S A, Huguet, F, Gruenberger, T, Arnold, D

Get full text

Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial by Demols, A., Borbath, I., Van den Eynde, M., Houbiers, G., Peeters, M., Marechal, R., Delaunoit, T., Goemine, J.-C., Laurent, S., Holbrechts, S., Paesmans, M., Van Laethem, J.-L.

“…There is a high unmet clinical need for treatments of advanced/metastatic biliary tract cancers after progression on first-line chemotherapy. Regorafenib has…”
Get full text

Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms by Heetfeld, M, Chougnet, C N, Olsen, I H, Rinke, A, Borbath, I, Crespo, G, Barriuso, J, Pavel, M, O'Toole, D, Walter, T

“…Data on gastroenteropancreatic neuroendocrine neoplasms (NEN) G3 (well-differentiated neuroendocrine tumors (NET G3) and neuroendocrine carcinoma (NEC)) are…”
Get full text

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study by Faivre, S., Niccoli, P., Castellano, D., Valle, J.W., Hammel, P., Raoul, J.-L., Vinik, A., Van Cutsem, E., Bang, Y.-J., Lee, S.-H., Borbath, I., Lombard-Bohas, C., Metrakos, P., Smith, D., Chen, J.-S., Ruszniewski, P., Seitz, J.-F., Patyna, S., Lu, D.R., Ishak, K.J., Raymond, E.

“…In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved…”
Get full text

Design and Investigation of Molybdenum Modified Platinum Surfaces for Modeling of CO Tolerant Electrocatalysts by Bakos, I., Borbáth, I., Vass, Á., Pászti, Z., Tompos, A.

“…Mo overlayers were prepared on smooth polycrystalline platinum and platinized platinum electrode surfaces by in situ electrochemical deposition of molybdenum…”
Get full text

VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial by Kelley, R.K., Yau, T., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A.X., Chan, S., Sukeepaisarnjaroen, W., Breder, V., Verset, G., Gane, E., Borbath, I., Gomez Rangel, J.D., Merle, P., Benzaghou, F.M., Banerjee, K., Hazra, S., Fawcett, J., Rimassa, L.

Get full text

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial by Kulke, M.H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J.W., De Herder, W.W., Pavel, M., Degtyarev, E., Brase, J.C., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R.P., Yao, J.C.

“…Several studies have demonstrated the antitumor activity of first-generation somatostatin analogs (SSAs), primarily targeting somatostatin receptor (sstr)…”
Get full text

The "Fonds Georges Brohée": a longstanding Belgian national initiative to stimulate research in hepatogastroenterology by Borbath, I, Fiasse, R, Van Hootegem, P

“…The Fonds Brohée/Brohée fund was created in 1964 at the initiative of 16 Belgian physicians, in the memory of Georges Brohée, the founder of the Belgian…”
Get more information

Novel Pt Electrocatalysts: Multifunctional Composite Supports for Enhanced Corrosion Resistance and Improved CO Tolerance by Vass, Á., Borbáth, I., Bakos, I., Pászti, Z., Sajó, I. E., Tompos, A.

“…The electrochemical peculiarities of novel 20 wt% Pt electrocatalysts supported on Ti 0.6 Mo 0.4 O 2 –C composite materials in low-potential CO oxidation…”
Get full text

Exclusive formation of alloy phases via anchoring technique—From bimetallic catalysts to electrocatalysis by Borbáth, I., Gubán, D., Bakos, I., Pászti, Z., Gajdos, G., Sajó, I.E., Vass, Á., Tompos, A.

“…[Display omitted] •Alloy-type Pt3Sn/C electrocatalysts were prepared by Controlled Surface Reactions.•Complete restoration of alloy phase in air exposed SnPt/C…”
Get full text

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study by van Marcke, C, Honoré, N, van der Elst, A, Beyaert, S, Derouane, F, Dumont, C, Aboubakar Nana, F, Baurain, J F, Borbath, I, Collard, P, Cornélis, F, De Cuyper, A, Duhoux, F P, Filleul, B, Galot, R, Gizzi, M, Mazzeo, F, Pieters, T, Seront, E, Sinapi, I, Van den Eynde, M, Whenham, N, Yombi, J C, Scohy, A, van Maanen, A, Machiels, J P

“…The viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk…”
Get full text

In Memoriam: René Fiasse (1936-2024) by Borbath, I, Deprez, P H, Dewit, O, Lanthier, N, Moreels, T, Stärkel, P, Piessevaux, H

Get more information

Watch-an-wait strategy for multiple rectal neuroendocrine tumors with widespread invasion by Torres, N, El Moussaoui, M, Basbous, S, Fridman, V, Borbath, I, Deflandre, J

Get more information

Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index by Weynand, B., Borbath, I., Bernard, V., Sempoux, C., Gigot, J.-F., Hubert, C., Lannoy, V., Deprez, P. H., Jouret-Mourin, A.

“…Objectives Assessment of proliferation by the Ki‐67 labelling index (Ki67‐LI) is an important parameter of pancreatic neuroendocrine tumour (pNET) prognosis on…”
Get full text

Pancreatic cancer organoids as a tool for developing personalized therapies by Meyers, N., Fages, A., Gérard, C., Dusetti, N., Borbath, I., Jacquemin, P.

Get full text

Effect of Mo incorporation on the electrocatalytic performance of Ti–Mo mixed oxide–carbon composite supported Pt electrocatalysts by Vass, Á., Borbáth, I., Pászti, Z., Bakos, I., Sajó, I. E., Németh, P., Tompos, A.

“…Ti (1−x) Mo x O 2 –C carbon composite supported platinum electocatalysts with systematically varied Ti/Mo ratio were prepared by a multistep sol–gel-based…”
Get full text

Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology by Borbath, I., Ceratti, A., Verslype, C., Demols, A., Delaunoit, T., Laurent, S., Deleporte, A., Vergauwe, P., Van Maanen, A., Sempoux, C., Van Cutsem, E., Van Laethem, J.L.

“…Cholangiocarcinomas are uncommon tumours with a poor prognosis, that frequently present epidermal growth factor receptor overexpression. In a multi-centre…”
Get full text

Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma by Borbath, I, Verbrugghe, L, Lai, R, Gigot, J.F, Humblet, Y, Piessevaux, H, Sempoux, C

“…Abstract Background Cholangiocarcinoma (CC) is a rare cancer of the liver. Surgery offers the only chance for cure. When surgery is unfeasible, chemotherapy is…”
Get full text

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial by Kulke, M.H., Ruszniewski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J.W., De Herder, W.W., Pavel, M., Degtyarev, E., Brase, J.C., Bubuteishvili-Pacaud, L., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R.P., Yao, J.C.

Get full text

Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial by Javle, M., Borbath, I., Clarke, S., Hitre, E., Louvet, C., Macarulla, T., Oh, D., Spratlin, J., Valle, J., Weiss, K., Berman, C., Howland, M., Ye, Y., Cho, T., Moran, S., Abou-Alfa, G.

Get full text